These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


138 related items for PubMed ID: 19898246

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
    Kang SJ, An JH, Kim J, Jang MO, Kim SE, Park KH, Jung SI, Jang HC.
    Jpn J Infect Dis; 2013; 66(4):317-9. PubMed ID: 23883843
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
    Pérez H, Vignoles M, Laufer N, Gómez A, Coll P, Lottner J, Rolón M, Salomón H, Cahn P.
    Antivir Ther; 2008; 13(1):135-9. PubMed ID: 18389908
    [Abstract] [Full Text] [Related]

  • 27. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1591-600. PubMed ID: 10983646
    [Abstract] [Full Text] [Related]

  • 31. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N, van der Merwe L, Brocklehurst P, Sint TT.
    Cochrane Database Syst Rev; 2011 Jul 06; (7):CD003510. PubMed ID: 21735394
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
    Martínez E, Ribera E, Clotet B, Estrada V, Sanz J, Berenguer J, Rubio R, Pulido F, Larrousse M, Curran A, Negredo E, Arterburn S, Ferrer P, Álvarez ML.
    HIV Med; 2015 Jul 06; 16(6):370-4. PubMed ID: 25496141
    [Abstract] [Full Text] [Related]

  • 34. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
    Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P, Prasithsirikul W, Sungkanuparph S, Bowonwatanuwong C, Klinbuayaem V, Kerr SJ, Sophonphan J, Bhakeecheep S, Hirschel B, Ruxrungtham K, HIV STAR Study Group.
    Antivir Ther; 2012 Jul 06; 17(7):1351-61. PubMed ID: 23075703
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 7.